PT  - JOURNAL ARTICLE
AU  - Hargrove, Diane M.
AU  - Alagarsamy, Sudarkodi
AU  - Croston, Glenn
AU  - Laporte, Régent
AU  - Qi, Steve
AU  - Srinivasan, Karthik
AU  - Sueiras-Diaz, Javier
AU  - Wiśniewski, Kazimierz
AU  - Hartwig, Jennifer
AU  - Lu, Mark
AU  - Posch, Alexander P.
AU  - Wiśniewska, Halina
AU  - Schteingart, Claudio D.
AU  - Rivière, Pierre J.-M.
AU  - Dimitriadou, Violetta
TI  - Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome
AID  - 10.1124/jpet.119.262238
DP  - 2020 May 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 193--203
VI  - 373
IP  - 2
4099  - http://jpet.aspetjournals.org/content/373/2/193.short
4100  - http://jpet.aspetjournals.org/content/373/2/193.full
SO  - J Pharmacol Exp Ther2020 May 01; 373
AB  - Glucagon-like peptide-2 (GLP-2) agonists have therapeutic potential in clinical indications in which the integrity or absorptive function of the intestinal mucosa is compromised, such as in short bowel syndrome (SBS). Native hGLP-2, a 33–amino acid peptide secreted from the small intestine, contributes to nutritional absorption but has a very short half-life because of enzymatic cleavage and renal clearance and thus is of limited therapeutic value. The GLP-2 analog teduglutide (Revestive/Gattex; Shire Inc.) has been approved for use in SBS since 2012 but has a once-daily injection regimen. Pharmacokinetic (PK) and pharmacodynamic studies confirm that apraglutide, a novel GLP-2 analog, has very low clearance, long elimination half-life, and high plasma protein binding compared with GLP-2 analogs teduglutide and glepaglutide. Apraglutide and teduglutide retain potency and selectivity at the GLP-2 receptor comparable to native hGLP-2, whereas glepaglutide was less potent and less selective. In rat intravenous PK studies, hGLP-2, teduglutide, glepaglutide, and apraglutide had clearances of 25, 9.9, 2.8, and 0.27 ml/kg per minute, respectively, and elimination half-lives of 6.4, 19, 16, and 159 minutes, respectively. The unique PK profile of apraglutide administered via intravenous and subcutaneous routes was confirmed in monkey and minipig and translated into significantly greater in vivo pharmacodynamic activity, measured as small intestinal growth in rats. Apraglutide showed greater intestinotrophic activity than the other peptides when administered at less-frequent dosing intervals because of its prolonged half-life. We postulate that apraglutide offers several advantages over existing GLP-2 analogs and is an excellent candidate for the treatment of gastrointestinal diseases, such as SBS.SIGNIFICANCE STATEMENT Apraglutide is a potent and selective GLP-2 agonist with an extremely low clearance and prolonged elimination half-life, which differentiates it from teduglutide (the only approved GLP-2 agonist). The enhanced pharmacokinetics of apraglutide will benefit patients by enabling a reduced dosing frequency and removing the need for daily injections.